Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
Not specified
Study Completion Date
July 31, 1998
Conditions
HIV InfectionsPregnancyHIV Seronegativity
Interventions
BIOLOGICAL
gp160 Vaccine (MicroGeneSys)
Trial Locations (2)
37232
Vanderbilt Univ Hosp, Nashville
06504
Yale Univ Med School, New Haven
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000777 - Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo) | Biotech Hunter | Biotech Hunter